Change Language

Select Language

COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.

Ischemic Heart Disease (IHD) Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

Market Overview:

The global ischemic heart disease (IHD) drugs market size reached US$ 5.8 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 7.6 Billion by 2027, exhibiting a growth rate (CAGR) of 4.57% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Ischemic heart disease (IHD), also known as coronary heart disease, is a condition that damages the heart muscle by interrupting the oxygen and blood supply. It involves molecular changes in the blood vessels or sudden closure and narrowing of coronary arteries by atheroma. The disease is often characterized by chronic chest pain and severe discomfort and can be fatal if left untreated. Various drugs are used to treat IHD depending on the intensity of the case. For instance, if cholesterol-modifying medication decreases cholesterol levels in the blood, then aspirin is prescribed to reduce clotting tendencies of the blood, and beta blockers are utilized to lower the heart rate and decrease blood pressure. IHD drugs also include calcium channel blockers and ranolazine that improve the efficiency of beta blockers and prevent further progression of coronary disease.

 

 
 

www.imarcgroup.com

Note: Values and trends in the above chart consists of dummy data and are only shown here for representation purpose. Kindly contact us for the actual market size and trends.

To get more information about this market, Request Sample

The growing inclination of the masses towards interventional medical procedures along with extensive utilization of anti-anginal medications for the treatment of IHD is one of the key factors driving the market growth. IHD drugs are being incorporated in cardiological treatment procedures such as angioplasty, atherectomy and balloon angioplasty to ensure a healthy recovery and prevent relapse in the future. Additionally, rising consumer awareness regarding the benefits of scheduled administration of these drugs is also creating a significant impact on their demand. Lifestyle habits such as excessive alcohol consumption and smoking along with physical inactiveness are also leading to an increasing prevalence of cardiovascular diseases. Furthermore, the expanding population of geriatrics around the globe, who are severely prone to heart ailments, is also boosting the demand for IHD drugs.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global ischemic heart disease (IHD) drugs market report, along with forecasts at the global and regional level from 2022-2027. Our report has categorized the market based on disease class and drug class.

Breakup by Disease Class:

 
 

www.imarcgroup.com

Note: Values and trends in the above chart consists of dummy data and are only shown here for representation purpose. Kindly contact us for the actual market size and trends.

To get more information about this market, Request Sample

  • Angina Pectoris 
  • Myocardial Infarction


Breakup by Drug Class:

  • Anti-Dyslipidemic Drugs
  • Calcium Channel Blockers
  • Beta-Blockers
  • ACE Inhibitors
  • ARBs
  • Vasodilators
  • Antithrombotic Agents


Breakup by Region:

 

 
 

www.imarcgroup.com

To get more information on the regional analysis of this market, Request Sample

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America


Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being Bayer AG, Eli Lilly and Company, Novartis International AG, Pfizer, Inc., Sanofi S.A., Actelion Pharmaceuticals Ltd., Baxter International Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Amgen Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co., and Eisai Co., Ltd.

Report Coverage:

Report Features Details
Base Year of the Analysis 2021
Historical Period 2016-2021
Forecast Period 2022-2027
Units US$ Billion
Segment Coverage Disease Class, Drug Class, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Companies Covered Bayer AG, Eli Lilly and Company, Novartis International AG, Pfizer, Inc., Sanofi S.A., Actelion Pharmaceuticals Ltd., Baxter International Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Amgen Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co., and Eisai Co., Ltd.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


Key Questions Answered in This Report:

  • How has the global ischemic heart disease (IHD) drugs market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global ischemic heart disease (IHD) drugs market?
  • What is the breakup of the market based on the disease class?
  • What is the breakup of the market based on the drug class?
  • What are the key regional markets in the global ischemic heart disease (IHD) drugs industry?
  • What are the various stages in the value chain of the global ischemic heart disease (IHD) drugs industry?
  • What are the key driving factors and challenges in the global ischemic heart disease (IHD) drugs industry?
  • What is the structure of the global ischemic heart disease (IHD) drugs industry and who are the key players?
  • What is the degree of competition in the global ischemic heart disease (IHD) drugs industry?

1   Preface
2   Scope and Methodology

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3   Executive Summary
4   Introduction

    4.1    Overview
    4.2    Key Industry Trends
5   Global Ischemic Heart Disease (IHD) Drugs Market
    5.1    Market Overview
    5.2    Market Performance
    5.3    Impact of COVID-19
    5.4    Market Forecast
6   Market Breakup by Disease Class
    6.1    Angina Pectoris
        6.1.1    Market Trends
        6.1.2    Market Forecast
    6.2    Myocardial Infarction
        6.2.1    Market Trends
        6.2.2    Market Forecast
7   Market Breakup by Drug Class
    7.1    Anti-Dyslipidemic Drugs
        7.1.1    Market Trends
        7.1.2    Market Forecast
    7.2    Calcium Channel Blockers
        7.2.1    Market Trends
        7.2.2    Market Forecast
    7.3    Beta-Blockers
        7.3.1    Market Trends
        7.3.2    Market Forecast
    7.4    ACE Inhibitors
        7.4.1    Market Trends
        7.4.2    Market Forecast
    7.5    ARBs
        7.5.1    Market Trends
        7.5.2    Market Forecast
    7.6    Vasodilators
        7.6.1    Market Trends
        7.6.2    Market Forecast
    7.7    Antithrombotic Agents
        7.7.1    Market Trends
        7.7.2    Market Forecast
8   Market Breakup by Region
    8.1    North America
        8.1.1    Market Trends
        8.1.2    Market Forecast
    8.2    Europe
        8.2.1    Market Trends
        8.2.2    Market Forecast
    8.3    Asia Pacific
        8.3.1    Market Trends
        8.3.2    Market Forecast
    8.4    Middle East and Africa
        8.4.1    Market Trends
        8.4.2    Market Forecast
    8.5    Latin America
        8.5.1    Market Trends
        8.5.2    Market Forecast
9   SWOT Analysis
    9.1    Overview
    9.2    Strengths
    9.3    Weaknesses
    9.4    Opportunities
    9.5    Threats
10  Value Chain Analysis
11  Porters Five Forces Analysis

    11.1    Overview
    11.2    Bargaining Power of Buyers
    11.3    Bargaining Power of Suppliers
    11.4    Degree of Competition
    11.5    Threat of New Entrants
    11.6    Threat of Substitutes
12  Price Analysis
13  Competitive Landscape

    13.1    Market Structure
    13.2    Key Players
    13.3    Profiles of Key Players
        13.3.1    Bayer AG  
        13.3.2    Eli Lilly and Company   
        13.3.3    Novartis International AG 
        13.3.4    Pfizer, Inc. 
        13.3.5    Sanofi S.A. 
        13.3.6    Actelion Pharmaceuticals Ltd.
        13.3.7    Baxter International Inc. 
        13.3.8    Boehringer Ingelheim International GmbH 
        13.3.9    Bristol-Myers Squibb Company 
        13.3.10   Amgen Inc.    
        13.3.11   F. Hoffmann-La Roche AG   
        13.3.12   GlaxoSmithKline Plc    
        13.3.13   Merck & Co.   
        13.3.14   Eisai Co., Ltd.  

List of Figures

Figure 1: Global: Ischemic Heart Disease Drugs Market: Major Drivers and Challenges
Figure 2: Global: Ischemic Heart Disease Drugs Market: Sales Value (in Billion US$), 2016 - 2021
Figure 3: Global: Ischemic Heart Disease Drugs Market: Breakup by Disease Class (in %), 2021
Figure 4: Global: Ischemic Heart Disease Drugs Market: Breakup by Drug Class (in %), 2021
Figure 5: Global: Ischemic Heart Disease Drugs Market: Breakup by Region (in %), 2021
Figure 6: Global: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 7: Global: Ischemic Heart Disease Drugs (Angina Pectoris) Market: Sales Value (in Million US$), 2016 & 2021
Figure 8: Global: Ischemic Heart Disease Drugs (Angina Pectoris) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 9: Global: Ischemic Heart Disease Drugs (Myocardial Infarction) Market: Sales Value (in Million US$), 2016 & 2021
Figure 10: Global: Ischemic Heart Disease Drugs (Myocardial Infarction) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 11: Global: Ischemic Heart Disease Drugs (Anti-Dyslipidemic Drugs) Market: Sales Value (in Million US$), 2016 & 2021
Figure 12: Global: Ischemic Heart Disease Drugs (Anti-Dyslipidemic Drugs) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 13: Global: Ischemic Heart Disease Drugs (Calcium Channel Blockers) Market: Sales Value (in Million US$), 2016 & 2021
Figure 14: Global: Ischemic Heart Disease Drugs (Calcium Channel Blockers) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 15: Global: Ischemic Heart Disease Drugs (Beta-Blockers) Market: Sales Value (in Million US$), 2016 & 2021
Figure 16: Global: Ischemic Heart Disease Drugs (Beta-Blockers) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 17: Global: Ischemic Heart Disease Drugs (ACE Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 18: Global: Ischemic Heart Disease Drugs (ACE Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 19: Global: Ischemic Heart Disease Drugs (ARBs) Market: Sales Value (in Million US$), 2016 & 2021
Figure 20: Global: Ischemic Heart Disease Drugs (ARBs) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 21: Global: Ischemic Heart Disease Drugs (Vasodilators) Market: Sales Value (in Million US$), 2016 & 2021
Figure 22: Global: Ischemic Heart Disease Drugs (Vasodilators) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 23: Global: Ischemic Heart Disease Drugs (Antithrombotic Agents) Market: Sales Value (in Million US$), 2016 & 2021
Figure 24: Global: Ischemic Heart Disease Drugs (Antithrombotic Agents) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 25: North America: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 26: North America: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 27: Europe: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 28: Europe: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 29: Asia Pacific: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 30: Asia Pacific: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 31: Middle East and Africa: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 32: Middle East and Africa: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 33: Latin America: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 34: Latin America: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 35: Global: Ischemic Heart Disease Drugs Industry: SWOT Analysis
Figure 36: Global: Ischemic Heart Disease Drugs Industry: Value Chain Analysis
Figure 37: Global: Ischemic Heart Disease Drugs Industry: Porter’s Five Forces Analysis

List of Tables

Table 1: Global: Ischemic Heart Disease Drugs Market: Key Industry Highlights, 2021 and 2027
Table 2: Global: Ischemic Heart Disease Drugs Market Forecast: Breakup by Disease Class (in Million US$), 2022-2027
Table 3: Global: Ischemic Heart Disease Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2022-2027
Table 4: Global: Ischemic Heart Disease Drugs Market Forecast: Breakup by Region (in Million US$), 2022-2027
Table 5: Global: Ischemic Heart Disease Drugs Market: Competitive Structure
Table 6: Global: Ischemic Heart Disease Drugs Market: Key Players


Note: We value your privacy and will never rent or sell your email address. Privacy policy

Need more help?

  •   Speak to our experienced analysts for insights on the current market scenarios.
  •   Include additional segments and countries to customize the report as per your requirement.
  •   Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  •   For further assistance, please connect with our analysts.

Purchase Options




$ 2499

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )


Drop us an email at

sales@imarcgroup.com

Social Links